Operating data: The company achieved total operating income of 227 million yuan in 2013, up 117.04% year on year; net profit attributable to shareholders of listed companies was 139 million yuan, up 1743.15% year on year, corresponding to earnings per share of 0.55 yuan. Net profit is expected to increase by 636.0-682.08% from January to March 2014, and is planned to change 10 to 0.8. Sales of traditional main products are improving. In 2013, the company stepped up its marketing efforts and brand promotion, placed leading product advertisements on CCTV channels 2 and 3, and also carried out a series of terminal promotion activities, which continued to maintain sales growth for leading products and films that were highly impressed; at the same time, it adhered to a diversified development strategy, increased new product promotion efforts, strengthened weak market development, effectively created new profit growth points, and enhanced brand image. The acquisition of Jinsha Pharmaceutical ushered in an inflection point in performance and enhanced core competitiveness. While adhering to the development of its main business, the company acquired the remaining 64.47% of Jinsha Pharmaceutical's shares in a timely manner in November. After taking full ownership of Jinsha Pharmaceutical, the company's product line expanded from medicine for colds for the throat to the field of traditional Chinese medicine for bone injuries; in terms of channels, from retail markets in South China and Southwest China to hospital terminals in all provinces and cities across the country, forming a win-win and mutually beneficial situation, greatly improving the company's core competitiveness and profitability. During the reporting period, operating income in 2013 increased by 117.04%, gross margin increased by 7.18 percentage points, sales, management and financial expense ratios decreased by 6.62, 7.10, and 1.21 percentage points, respectively, and net profit surged 1743.15 percentage points. In 2014, the plum blossom planting base is expected to expand production from 3,000 mu to 5,000 mu. The company will continue to cooperate with universities and scientific research institutes such as South China University of Technology, Jinan University, South China Agricultural University, etc., to cultivate and develop plum tree resources and promote research on key technologies for large-scale production of high-purity natural dextrophurium (natural borneol) in an orderly manner; strive to expand the planting base of 2,000 acres of plum blossoms on the basis of the original 3,000-acre planting base, and build an excellent plum tree seedling cultivation site to further carry out the construction of a plum film extraction workshop; for the 2015 new pharmacopoeia, the quality standards for double throatophore dispersion and the company's lead in the development of Urannosaurus Do quality standards Preliminary preparation. Profit forecasts and valuations. We expect the company's EPS for 2014-2016 to be 0.58 yuan/0.75 yuan/1.08 yuan respectively, corresponding to PE 39.3 times/30.6 times/21.1 times. The plum tree planting and active ingredient extraction project has been included in the Guangdong Sailing Plan. It is a key project for secondary greening and building a green GDP in the province. It has received full support from governments at all levels in Guangdong Province and local farmers, and has enjoyed many benefits such as VAT and income tax exemptions. The potential value-added and growth space is huge, maintaining a “buy” rating, and the target price has been raised to 32.4 yuan.